News | April 07, 2025
Fluor to provide EPCM services for pharmaceutical facility in Indiana
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Construction is now underway with the facility scheduled to be operational by 2025
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Exploring new opportunities within the fast-growing market of microfluidics
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Subscribe To Our Newsletter & Stay Updated
